Patents by Inventor Jun Kuai
Jun Kuai has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9428577Abstract: The present invention provides antibodies, or antigen-binding fragment thereof, which specifically bind to PDGF-B. The invention further provides a method of obtaining such antibodies and nucleic acids encoding the same. The invention further relates to compositions and therapeutic methods for use of these antibodies for the treatment and/or prevention of PDGF-B mediated diseases, disorders or conditions.Type: GrantFiled: November 8, 2013Date of Patent: August 30, 2016Assignee: Pfizer Inc.Inventors: Robert Arch, Gregory Carven, Jun Kuai, Lydia Mosyak, Shinji Ogawa, Dirk Ponsel, Robert Rauchenberger
-
Patent number: 9102583Abstract: A process for producing ethylene glycol includes contacting an oxalate with a fluidized bed catalyst under the following conditions: a reaction temperature of from about 170 to about 270° C., a weight space velocity of oxalate of from about 0.2 to about 7 hours?1, a hydrogen/ester molar ratio of about 20˜200:1, a reaction pressure of from about 1.5 to about 10 MPa, and a reaction temperature difference T of from about 1 to about 15° C. The fluidized bed catalyst includes: a) from about 5 to about 80 parts by weight of copper and the oxide thereof, b) from about 10 to about 90 parts by weight of at least one carrier selected from silica, molecular sieve or alumina, c) from about 0.01 to about 30 parts by weight of bismuth and tungsten metallic elements or the oxides thereof, or cerium and niobium metallic elements or the oxides thereof.Type: GrantFiled: February 24, 2012Date of Patent: August 11, 2015Assignees: CHINA PETROLEUM & CHEMICAL CORPORATION, SHANGHAI RESEARCH INSTITUTE OF PETROCHEMICAL TECHNOLOGY, SINOPECInventors: Weimin Yang, Juntao Liu, Wanmin Wang, Jun Kuai
-
Method for selective hydrogenation of phenylacetylene using composite bed in the presence of styrene
Patent number: 8916736Abstract: The present invention discloses a process for the selective hydrogenation of phenylacetylene in the presence of styrene conducted in a combined bed, which process comprises under hydrogenation reaction conditions, passing a hydrocarbon fraction feedstock containing phenylacetylene and styrene through a combined bed reactor containing a catalyst A and a catalyst B to contact the feedstock with the catalyst A and the catalyst B in turn, wherein the catalyst A is a nickel-based catalyst, the catalyst B is at least one selected from the group consisting of palladium-based catalysts and copper-based catalysts, and a weight ratio of the catalyst A loaded to the catalyst B loaded is from 0.5:1 to 5:1.Type: GrantFiled: December 17, 2009Date of Patent: December 23, 2014Assignees: Shanghai Research Institute of Petrochemical Technology, Sinopec, China Petroleum & Chemical CorporationInventors: Siqin Li, Juntao Liu, Zhiyan Zhu, Junhua Zhu, Jun Kuai -
Patent number: 8871968Abstract: The present invention relates to a process of producing oxalate by CO gas phase method for chiefly solving the technical problem of the low utilization efficiency of nitrogen oxides or nitrous acid esters in the prior art.Type: GrantFiled: April 13, 2011Date of Patent: October 28, 2014Assignees: China Petroleum & Chemical Corporation, Shanghai Research Institute of Petrochemical Technology SinopecInventors: Juntao Liu, Fengxia Sun, Jun Kuai
-
Publication number: 20140134176Abstract: The present invention provides antibodies, or antigen-binding fragment thereof, which specifically bind to PDGF-B. The invention further provides a method of obtaining such antibodies and nucleic acids encoding the same. The invention further relates to compositions and therapeutic methods for use of these antibodies for the treatment and/or prevention of PDGF-B mediated diseases, disorders or conditions.Type: ApplicationFiled: November 8, 2013Publication date: May 15, 2014Applicant: Pfizer Inc.Inventors: Robert ARCH, Gregory CARVEN, Jun KUAI, Lydia MOSYAK, Shinji OGAWA, Dirk PONSEL, Robert RAUCHENBERGER
-
Publication number: 20130331617Abstract: A process for producing ethylene glycol includes contacting an oxalate with a fluidized bed catalyst under the following conditions: a reaction temperature of from about 170 to about 270° C., a weight space velocity of oxalate of from about 0.2 to about 7 hours?1, a hydrogen/ester molar ratio of about 20˜200:1, a reaction pressure of from about 1.5 to about 10 MPa, and a reaction temperature difference T of from about 1 to about 15° C. The fluidized bed catalyst includes: a) from about 5 to about 80 parts by weight of copper and the oxide thereof, b) from about 10 to about 90 parts by weight of at least one carrier selected from silica, molecular sieve or alumina, c) from about 0.01 to about 30 parts by weight of bismuth and tungsten metallic elements or the oxides thereof, or cerium and niobium metallic elements or the oxides thereof.Type: ApplicationFiled: February 24, 2012Publication date: December 12, 2013Applicants: Shanghai Research Institute of Petrochemical Technology, Sinopec, China Petroleum & Chemical CorporationInventors: Weimin Yang, Juntao Liu, Wanmin Wang, Jun Kuai
-
Patent number: 8574522Abstract: A process for selective oxidative dehydrogenation of a hydrogen-containing CO mixed gas, comprising contacting a hydrogen-containing CO mixed gas raw material with at least one catalyst entity having an increased activity gradient disposed in a reactor under at least one reaction condition chosen from a reaction temperature ranging from 100 to 300° C., a volume space velocity ranging from 100 to 10000 h?1, and a reaction pressure ranging from ?0.08 to 5.0 MPa, wherein the molar ratio of oxygen to hydrogen in the raw material ranges from 0.5:1 to 5:1.Type: GrantFiled: April 15, 2011Date of Patent: November 5, 2013Assignees: China Petroleum & Chemical Corporation, Shanghai Research Institute of Petrochemical Technology SinopecInventors: Juntao Liu, Siqin Li, Linna Zhang, Lei Li, Jun Kuai
-
Publication number: 20130197265Abstract: The present invention relates to a process of producing oxalate by CO gas phase method for chiefly solving the technical problem of the low utilization efficiency of nitrogen oxides or nitrous acid esters in the prior art.Type: ApplicationFiled: April 13, 2011Publication date: August 1, 2013Applicants: SHANGHAI RESEARCH INSTITUTE OF PETROCHEMICAL TECHNOLOGY SINOPEC, CHINA PETROLEUM & CHEMICAL CORPORATIONInventors: Juntao Liu, Fengxia Sun, Jun Kuai
-
METHOD FOR SELECTIVE HYDROGENATION OF PHENYLACETYLENE USING COMPOSITE BED IN THE PRESENCE OF STYRENE
Publication number: 20110319684Abstract: The present invention discloses a process for the selective hydrogenation of phenylacetylene in the presence of styrene conducted in a combined bed, which process comprises under hydrogenation reaction conditions, passing a hydrocarbon fraction feedstock containing phenylacetylene and styrene through a combined bed reactor containing a catalyst A and a catalyst B to contact the feedstock with the catalyst A and the catalyst B in turn, wherein the catalyst A is a nickel-based catalyst, the catalyst B is at least one selected from the group consisting of palladium-based catalysts and copper-based catalysts, and a weight ratio of the catalyst A loaded to the catalyst B loaded is from 0.5:1 to 5:1.Type: ApplicationFiled: December 17, 2009Publication date: December 29, 2011Inventors: Siqin Li, Juntao Jiu, Zhiyan Zhu, Junhua Zhu, Jun Kuai -
Publication number: 20110263726Abstract: A process for selective oxidative dehydrogenation of a hydrogen-containing CO mixed gas, comprising contacting a hydrogen-containing CO mixed gas raw material with at least one catalyst entity having an increased activity gradient disposed in a reactor under at least one reaction condition chosen from a reaction temperature ranging from 100 to 300° C., a volume space velocity ranging from 100 to 10000 h?1, and a reaction pressure ranging from ?0.08 to 5.0 MPa, wherein the molar ratio of oxygen to hydrogen in the raw material ranges from 0.5:1 to 5:1.Type: ApplicationFiled: April 15, 2011Publication date: October 27, 2011Inventors: Juntao Liu, Siqin Li, Linna Zhang, Lei Li, Jun Kuai
-
Publication number: 20080247955Abstract: The present invention provides methods of treating inflammatory diseases/disorders in a subject by inhibiting/antagonizing TREM-1 expression/activity/signal transduction and/or DAP12/TyroBP expression and/or activity. Methods of detecting the presence of inflammatory disease in a subject by detecting TREM-1 and/or DAP12/TyroBP expression and/or activity in the subject or a sample obtained therefrom, wherein increased expression or activity is indicative of the inflammatory disease are also included. The present invention further provides methods for assessing the efficacy of a TREM-1-modulating agent administered to a patient by detecting levels of secreted phosphoprotein 1 (SPP1) and/or one or more other biomarkers in the patient or in a sample from the patient.Type: ApplicationFiled: January 16, 2008Publication date: October 9, 2008Inventors: Jun Kuai, Ken Dower, Jeffrey Lawrence Feldman, Debra Denene Pittman, Moitreyee Chatterjee-Kishore, David Gunther Winkler, Lih-Ling Lin, Scott Alan Jelinsky, Cara Williams
-
Publication number: 20080248460Abstract: The invention relates to compositions and methods comprising lymphotoxin-beta receptor (LT?R) modulators, which activate or inhibit LT?R signaling. LT?R modulators are useful for treating lymphocyte mediated immunological diseases and cancer, and more particularly, for regulating mitochondrial-mediated apoptosis. This invention relates to soluble forms of the LT?R complex proteins that act as LT?R activating or inhibiting agents. This invention also relates to the use of soluble molecules, directed against either the LT?R, its ligands, LIGHT and LT?1?2, or its intracellular binding partners, that function to regulate LT?R signaling. A novel screening method for selecting soluble receptors, antibodies and other agents that modulate LT?R signaling is provided.Type: ApplicationFiled: July 6, 2007Publication date: October 9, 2008Inventors: Jun Kuai, Joseph L. Wooters, Elliott Nickbarg, Yongchang Qiu, Lih-Ling Lin
-
Patent number: 7273707Abstract: The invention relates to compositions and methods comprising lymphotoxin-beta receptor (LT?R) modulators, which activate or inhibit LT?R signaling. LT?R modulators are useful for treating lymphocyte mediated immunological diseases and cancer, and more particularly, for regulating mitochondrial-mediated apoptosis. This invention relates to soluble forms of the LT?R complex proteins that act as LT?R activating or inhibiting agents. This invention also relates to the use of soluble molecules, directed against either the LT?R, its ligands, LIGHT and LT?1?2, or its intracellular binding partners, that function to regulate LT?R signaling. A novel screening method for selecting soluble receptors, antibodies and other agents that modulate LT?R signaling is provided.Type: GrantFiled: February 10, 2003Date of Patent: September 25, 2007Assignee: WyethInventors: Jun Kuai, Joseph L. Wooters, Elliott Nickbarg, Yongchang Qiu, Lih-Ling Lin
-
Publication number: 20060078944Abstract: The present invention relates to, among other embodiments, protein complexes which include tumor necrosis factor alpha (TNF-?) and/or tumor necrosis factor alpha receptor (TNFR). Preferably, the complexes comprise at least one polypeptide selected from the group consisting of: NF-?B activating kinase (NAK), RasGAP3, TRCP1, and TRCP2. The present invention further provides assays of identifying a compound for modulating the stability and activity of the complex. Also provided are methods of modulating apoptosis and inflammation, as well as treating TNF-? related diseases.Type: ApplicationFiled: August 1, 2003Publication date: April 13, 2006Inventors: Jun Kuai, Lih-Ling Lin, Joseph Wooters, Elliott Nickbarg
-
Publication number: 20040038299Abstract: The invention relates to compositions and methods comprising lymphotoxin-beta receptor (LT&bgr;R) modulators, which activate or inhibit LT&bgr;R signaling. LT&bgr;R modulators are useful for treating lymphocyte mediated immunological diseases and cancer, and more particularly, for regulating mitochondrial-mediated apoptosis. This invention relates to soluble forms of the LT&bgr;R complex proteins that act as LT&bgr;R activating or inhibiting agents. This invention also relates to the use of soluble molecules, directed against either the LT&bgr;R, its ligands, LIGHT and LT&bgr;1&agr;2, or its intracellular binding partners, that function to regulate LT&bgr;R signaling. A novel screening method for selecting soluble receptors, antibodies and other agents that modulate LT&bgr;R signaling is provided.Type: ApplicationFiled: February 10, 2003Publication date: February 26, 2004Inventors: Jun Kuai, Joseph L. Wooters, Elliott Nickbarg, Yongchang Qiu, Lih-Ling Lin